Share on LinkedInShare on LinkedIn

ARTICLE · 12 NOVEMBER 2018

Federal Court Recognizes Limits Of Decisions Under The Old PM(NOC) Regulations

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

Prothonotary Milczynski's decision is only the second such ruling under section 6.08, and the previous motion, which relates to a "skinny label" submission, was also dismissed.

CanadaIntellectual Property

In a recent decision of the Federal Court, Amgen Inc v Pfizer Canada Inc, 2018 FC 1078, 2018 FC 1078, Prothonotary Milczynski dismissed Pfizer's motion for summary dismissal of the proceedings under section 6.08 of the recently amended PM(NOC) Regulations. Prothonotary Milczynski's decision is only the second such ruling under section 6.08, and the previous motion, which relates to a "skinny label" submission, was also dismissed.1

Background of the Proceeding

Pfizer, acting here as a second person, sought to market a biosimilar product to Amgen's Neupogen and Neulasta products, containing filgrastim and pelfilgrastim respectively. In doing so, Pfizer served a Notice of Allegation regarding Amgen's 1,341,537 patent (the "537 Patent"), listed on the Patent Register for both products. As this action is under the Amended Regulations, Amgen brought its claim for infringement of the patent, and Pfizer counterclaimed for invalidity.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from